This study seeks to determine whether adult, non-psychotic, first-degree relatives of schizophrenic patients who show specific neurocognitive deficits and negative symptoms will show improvements in these areas following a 6-month, double-blind trial of a low dose (up to 2.0 mg) of risperidone.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Enrollment
100
Risperidone will be given in low dosage to a random sample of family members of Schizophrenic patients
Mental Health Institute
Changsha, Hunan, China
RECRUITINGNeuropsychological - cognitive measures
Time frame: 2003-2010
Psychiatric Symptoms
Time frame: 2003-2010
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.